Access Program Information
This will be an open-label, single-arm, multicenter intermediate access protocol which
provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1
(NF1) who have inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any
alternative therapeutic options. All patients will continue to receive drug while they are
deriving clinical benefit .
Approximately 50 patients in the US will be treated as part of this protocol